Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AUDIOEYE INCAEYE · Entity 6844 | Director | October 01, 2026 | October 03, 2026 |
| IRADIMED CORPIRMD · Entity 4896 | Director | December 11, 2025 | December 15, 2025 |
| NATUS MEDICAL INCBABY · Entity 125256 | Director · President and CEO | April 30, 2018 | May 02, 2018 |
| OSI SYSTEMS INCOSIS · Entity 4160 | Director | August 20, 2026 | August 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AUDIOEYE INC
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 218,684 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 1,000 · Balance 218,684 F1: The securities relate to a quarterly grant of shares of common stock under the AudioEye, Inc. 2020 Equity Incentive Plan, which shares were fully vested on the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities relate to a quarterly grant of shares of common stock under the AudioEye, Inc. 2020 Equity Incentive Plan, which shares were fully vested on the grant date.
IRADIMED CORP
Report date December 11, 2025 · Filed December 15, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,932 |
Reported balance
After 2025-12-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-11 · Grant · Acquired 1,026 · Balance 1,932 F1: Restricted stock units convert into common stock on a one-for-one basis. F2: On December 11, 2025, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 11, 2026. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units convert into common stock on a one-for-one basis.
F2: On December 11, 2025, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 11, 2026. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.
NATUS MEDICAL INC
Report date April 30, 2018 · Filed May 02, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par value per shareSEC Table I · non-derivative | Direct | 639,257 |
Ending reported balance
After 2018-04-30 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2018-04-30 · Exercise / conversion · Acquired 47,500 · Balance 686,757 Row 2 · 2018-04-30 · Sale · Disposed 47,500 · Balance 639,257 F1: This transaction was executed in multiple trades at prices ranging from $32.90 to $34.15. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 3 · 2018-04-30 · Exercise / conversion · Acquired 76,827 · Balance 716,084 Row 4 · 2018-04-30 · Sale · Disposed 76,827 · Balance 639,257 F2: This transaction was executed in multiple trades at prices ranging from $33.05 to $33.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 5 · 2018-04-30 · Exercise / conversion · Acquired 35,673 · Balance 674,930 Row 6 · 2018-04-30 · Sale · Disposed 35,673 · Balance 639,257 F3: This transaction was executed in multiple trades at prices ranging from $32.65 to $33.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Nonqualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $10.69 · Expires 2018-06-07 | Direct | 112,500 |
Reported balance
After 2018-04-30 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-04-30 · Exercise / conversion · Disposed 47,500 · Balance 112,500 |
| Nonqualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $10.69 · Expires 2018-06-07 | Direct | 35,673 |
Reported balance
After 2018-05-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-05-01 · Exercise / conversion · Disposed 76,827 · Balance 35,673 |
| Nonqualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $10.69 · Expires 2018-06-07 | Direct | 0 |
Reported balance
After 2018-05-02 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-05-02 · Exercise / conversion · Disposed 35,673 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $32.90 to $34.15. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2: This transaction was executed in multiple trades at prices ranging from $33.05 to $33.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $32.65 to $33.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
OSI SYSTEMS INC
Report date August 20, 2026 · Filed August 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,295 |
Reported balance
After 2026-08-20 transaction · row 1
1 source rowRow 1 · 2026-08-20 · Tax withholding · Disposed 90 · Balance 5,295 F1: Pursuant with a net settlement, shares of stock were tendered to pay for the tax withholding. No shares of stock were sold. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant with a net settlement, shares of stock were tendered to pay for the tax withholding. No shares of stock were sold.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Caesars Entertainment, Inc.
Report date July 20, 2020 · Filed July 23, 2020
Section 16 reporting ended · disclosed 2020-07-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 128,082 |
Ending reported balance
After 2020-07-20 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2020-07-20 · Exercise / conversion · Acquired 9,256 · Balance 91,256 F1: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with Eldorado Resorts, Inc. (n/k/a Caesars Entertainment, Inc., the "Company"), all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock. Row 2 · 2020-07-20 · Exercise / conversion · Acquired 17,980 · Balance 109,236 F2: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock. Row 3 · 2020-07-20 · Exercise / conversion · Acquired 6,984 · Balance 116,220 F3: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock. Row 4 · 2020-07-20 · Exercise / conversion · Acquired 4,612 · Balance 120,832 F4: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock. Row 5 · 2020-07-20 · Exercise / conversion · Acquired 4,305 · Balance 125,137 F5: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock. Row 6 · 2020-07-20 · Exercise / conversion · Acquired 2,945 · Balance 128,082 F6: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2020-07-20 | Direct | 0 |
Reported balance
After 2020-07-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-07-20 · Exercise / conversion · Disposed 9,256 · Balance 0 F1: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with Eldorado Resorts, Inc. (n/k/a Caesars Entertainment, Inc., the "Company"), all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2020-07-20 | Direct | 0 |
Reported balance
After 2020-07-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-07-20 · Exercise / conversion · Disposed 17,980 · Balance 0 F2: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2020-07-20 | Direct | 0 |
Reported balance
After 2020-07-20 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-07-20 · Exercise / conversion · Disposed 6,984 · Balance 0 F3: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2020-07-20 | Direct | 0 |
Reported balance
After 2020-07-20 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-07-20 · Exercise / conversion · Disposed 4,612 · Balance 0 F4: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2020-07-20 | Direct | 0 |
Reported balance
After 2020-07-20 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2020-07-20 · Exercise / conversion · Disposed 4,305 · Balance 0 F5: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2020-07-20 | Direct | 0 |
Reported balance
After 2020-07-20 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2020-07-20 · Exercise / conversion · Disposed 2,945 · Balance 0 F6: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with Eldorado Resorts, Inc. (n/k/a Caesars Entertainment, Inc., the "Company"), all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock.
F2: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock.
F3: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock.
F4: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock.
F5: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock.
F6: Each Restricted Stock Unit represented the economic equivalent of one share of the Company's common stock. In connection with the reporting person's separation from service with the Company, all of the shares underlying the Restricted Stock Unit were settled for shares of the Company's common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 23, 2025 Filed May 28, 2025 20:50 UTC | AUDIOEYE INC AEYE · Entity 6844 | GrantCommon Stock | 5,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-014732 · form4-05282025_080556.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,516 F1 · shares: Reflects the grant of restricted stock units ("RSUs") under the AudioEye, Inc. 2020 Equity Incentive Plan, which RSUs will vest on the earlier of (a) one year following the date of the grant or (b) immediately prior to the next annual meeting of stockholders following the date of grant, provided the director's service has not terminated prior to such date. Any of these vested RSUs will be settled on the earlier of (i) the 7th anniversary of the grant date, (ii) immediately prior to the closing of a change in control, but in no case later than 90 days following the change in control, or (iii) the calendar year following the year of death, with payment made no later than the end of the year following the year of death. Read SEC document |
| May 23, 2025 Filed Jun 5, 2025 21:49 UTC Amendment | AUDIOEYE INC AEYE · Entity 6844 | GrantCommon Stock | 5,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015823 · form4a-06052025_090621.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,516 F1 · shares: The purpose of this Form 4/A is to correct one of the potential settlement dates of the restricted stock units ("RSUs") reported in footnote (1) to a Form 4 filed on May 28, 2025 (the "Original Form 4"). All other information reported in the Original Form 4 is unchanged. Footnote (1) is hereby corrected as follows: Reflects the grant of RSUs, which RSUs will vest on the earlier of (a) 1 year following the date of the grant or (b) immediately prior to the next annual meeting of stockholders following the date of grant, provided the director's service has not terminated prior to such date. Any of these vested RSUs will be settled on the earlier of (i) the 3rd anniversary of the grant date, (ii) immediately prior to the closing of a change in control, but in no case later than 90 days following the change in control, or (iii) the calendar year following the year of death, with payment made no later than the end of the year following the year of death. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:09 UTC | AUDIOEYE INC AEYE · Entity 6844 | GrantCommon Stock | 667 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-009927 · form4-04032025_080403.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,849 F1 · shares: The securities relate to a quarterly grant of restricted stock units ("RSUs") under the AudioEye, Inc. 2020 Equity Incentive Plan, which RSUs vested on the grant date and will be settled on the earlier of (i) the third anniversary of the grant date, (ii) immediately prior to the closing of a change in control, but in no case later than 90 days following the change in control, and (iii) the calendar year following the year of death, with payment being made in no case later than the end of the year following the year of death. Read SEC document |
| March 21, 2025 Filed Mar 25, 2025 23:09 UTC | AUDIOEYE INC AEYE · Entity 6844 | OtherPut Option (obligation to buy) · Derivative | 18 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001415889-25-008962 · form4-03252025_110316.xml · derivative · entry 2 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,800 shares Expires 2025-03-21 Read SEC document |
| March 21, 2025 Filed Mar 25, 2025 23:09 UTC | AUDIOEYE INC AEYE · Entity 6844 | OtherCommon Stock | 1,800 | $15.00 | $27,000.00 |
DisclosureSEC source: 0001415889-25-008962 · form4-03252025_110316.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,182 Read SEC document |
| March 19, 2025 Filed Mar 21, 2025 20:33 UTC | AUDIOEYE INC AEYE · Entity 6844 | OtherPut Option (obligation to buy) · Derivative | 21 | $0.00 Strike: $17.50 | $0.00 |
DisclosureSEC source: 0001415889-25-008775 · form4-03212025_080337.xml · derivative · entry 4 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,100 shares Expires 2025-03-21 Read SEC document |
| March 19, 2025 Filed Mar 21, 2025 20:33 UTC | AUDIOEYE INC AEYE · Entity 6844 | OtherPut Option (obligation to buy) · Derivative | 112 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001415889-25-008775 · form4-03212025_080337.xml · derivative · entry 3 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,800 Underlying: Common Stock · 11,200 shares Expires 2025-03-21 Read SEC document |
| March 19, 2025 Filed Mar 21, 2025 20:33 UTC | AUDIOEYE INC AEYE · Entity 6844 | PurchaseCommon Stock | 2,100 | $17.50 | $36,750.00 |
DisclosureSEC source: 0001415889-25-008775 · form4-03212025_080337.xml · nonDerivative · entry 2 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,382 Read SEC document |
| March 19, 2025 Filed Mar 21, 2025 20:33 UTC | AUDIOEYE INC AEYE · Entity 6844 | PurchaseCommon Stock | 11,200 | $15.00 | $168,000.00 |
DisclosureSEC source: 0001415889-25-008775 · form4-03212025_080337.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,282 Read SEC document |
| March 14, 2025 Filed Mar 17, 2025 21:54 UTC | AUDIOEYE INC AEYE · Entity 6844 | OtherPut Option (obligation to buy) · Derivative | 39 | $0.00 Strike: $17.50 | $0.00 |
DisclosureSEC source: 0001415889-25-008241 · form4-03172025_090340.xml · derivative · entry 2 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,100 Underlying: Common Stock · 3,900 shares Expires 2025-03-21 Read SEC document |
| March 14, 2025 Filed Mar 17, 2025 21:54 UTC | AUDIOEYE INC AEYE · Entity 6844 | OtherCommon Stock | 3,900 | $17.50 | $68,250.00 |
DisclosureSEC source: 0001415889-25-008241 · form4-03172025_090340.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,082 Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 22:10 UTC | AUDIOEYE INC AEYE · Entity 6844 | GrantCommon Stock | 1,270 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-007001 · form4-03052025_100322.xml · nonDerivative · entry 2 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,182 F2 · shares: Reflects the grant of 1,270 RSUs under the 2020 Plan for the prorated annual equity award to non-employee directors, which RSUs will vest on the earlier of (i) one year following the date of the grant or (ii) immediately prior to the next annual meeting of stockholders following the date of grant, provided the director's service has not terminated prior to such date, and any of these vested RSUs will be settled on the earlier of (1) the 7th anniversary of the grant date, (2) immediately prior to the closing of a change in control, but in no case later than 90 days following the change in control, or (3) the calendar year following the year of death, with payment made no later than the end of the year following the year of death. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 22:10 UTC | AUDIOEYE INC AEYE · Entity 6844 | GrantCommon Stock | 215 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-007001 · form4-03052025_100322.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,912 F1 · shares: Reflects the grant of 215 restricted stock units ("RSUs") under the AudioEye, Inc. 2020 Equity Incentive Plan (the "2020 Plan") for the prorated quarterly equity award to non-employee directors, which RSUs vested on the grant date and will be settled on the earlier of (i) the third anniversary of the grant date, (ii) immediately prior to the closing of a change in control, but in no case later than 90 days following the change in control, and (iii) the calendar year following the year of death, with payment being made in no case later than the end of the year following the year of death. Read SEC document |
| December 13, 2024 Filed Dec 13, 2024 22:30 UTC | OSI SYSTEMS INC OSIS · Entity 4160 | Tax withholdingCommon Stock | 15 | $187.75 | $2,816.25 |
DisclosureSEC source: 0001415889-24-029345 · form4-12132024_101236.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,381 F1 · shares: Pursuant with a net settlement, shares of stock were tendered to pay for the tax withholding. No shares of stock were sold. Read SEC document |
| December 11, 2024 Filed Dec 13, 2024 21:00 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantRestricted Stock Units · Derivative | 1,811 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-029269 · form4-12132024_041203.xml · derivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,008 Underlying: Common Stock · 1,811 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On December 11, 2024, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F2 · derivative.expiration_date: On December 11, 2024, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 10, 2024 Filed Dec 12, 2024 21:43 UTC | OSI SYSTEMS INC OSIS · Entity 4160 | SaleCommon Stock | 2,000 | $182.62 | $365,240.00 |
DisclosureSEC source: 0001415889-24-029140 · form4-12122024_091225.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,396 F1 · price: This transaction was executed in multiple trades at prices ranging from $182.50 to $183.10. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and price at which the transaction was effected. Read SEC document |
| December 07, 2024 Filed Dec 11, 2024 02:00 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionRestricted Stock Units · Derivative | 1,196 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-028903 · form4-12102024_091209.xml · derivative · entry 4 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,197 Underlying: Common Stock · 1,196 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On December 7, 2023, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2024. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F3 · derivative.expiration_date: On December 7, 2023, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2024. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 07, 2024 Filed Dec 11, 2024 02:00 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionRestricted Stock Units · Derivative | 1,751 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-028903 · form4-12102024_091209.xml · derivative · entry 3 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,751 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On December 7, 2022, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F2 · derivative.expiration_date: On December 7, 2022, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 07, 2024 Filed Dec 11, 2024 02:00 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionCommon Stock | 1,196 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-028903 · form4-12102024_091209.xml · nonDerivative · entry 2 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,295 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 07, 2024 Filed Dec 11, 2024 02:00 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionCommon Stock | 1,751 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-028903 · form4-12102024_091209.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 07, 2024 Filed Apr 4, 2025 20:45 UTC Amendment | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionCommon Stock | 1,196 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-010211 · form4a-04042025_040403.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On December 10, 2024, the reporting person timely filed a Form 4, which inadvertently overstated in column 5 the number of shares of Iradimed Corporation (the "Issuer") common stock directly owned by the reporting person following the reported transaction. No transactions regarding the Issuer's securities were omitted. This inadvertent overstatement has been corrected in this amended filing. F1 · balance_after: On December 10, 2024, the reporting person timely filed a Form 4, which inadvertently overstated in column 5 the number of shares of Iradimed Corporation (the "Issuer") common stock directly owned by the reporting person following the reported transaction. No transactions regarding the Issuer's securities were omitted. This inadvertent overstatement has been corrected in this amended filing. Read SEC document |
| August 14, 2024 Filed Aug 17, 2024 00:00 UTC | OSI SYSTEMS INC OSIS · Entity 4160 | GrantCommon Stock | 1,439 | $139.02 | $200,049.78 |
DisclosureSEC source: 0001415889-24-021523 · form4-08162024_080806.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,566 Read SEC document |
| July 28, 2024 Filed Oct 29, 2024 21:50 UTC | OSI SYSTEMS INC OSIS · Entity 4160 | Tax withholdingCommon Stock | 170 | $150.33 | $25,556.10 |
DisclosureSEC source: 0001415889-24-025700 · form4-10292024_051001.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,396 F1 · shares: Pursuant with a net settlement, shares of stock were tendered to pay for the tax withholding. No shares of stock were sold. Read SEC document |
| July 08, 2024 Filed Jul 9, 2024 20:56 UTC | OSI SYSTEMS INC OSIS · Entity 4160 | Tax withholdingCommon Stock | 476 | $137.62 | $65,507.12 |
DisclosureSEC source: 0001415889-24-019435 · form4-07092024_080721.xml · nonDerivative · entry 2 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,127 F1 · shares: Pursuant with a net settlement, shares of stock were tendered to pay for the tax withholding. No shares of stock were sold. Read SEC document |
| July 06, 2024 Filed Jul 9, 2024 20:56 UTC | OSI SYSTEMS INC OSIS · Entity 4160 | Tax withholdingCommon Stock | 231 | $137.62 | $31,790.22 |
DisclosureSEC source: 0001415889-24-019435 · form4-07092024_080721.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,603 F1 · shares: Pursuant with a net settlement, shares of stock were tendered to pay for the tax withholding. No shares of stock were sold. Read SEC document |
| May 08, 2024 Filed May 9, 2024 22:16 UTC | OSI SYSTEMS INC OSIS · Entity 4160 | SaleCommon Stock | 4,215 | $134.29 | $566,032.35 |
DisclosureSEC source: 0001415889-24-012758 · form4-05092024_100523.xml · nonDerivative · entry 2 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,834 F2 · price: This transaction was executed in multiple trades at prices ranging from $134.18 to $134.62. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and price at which the transaction was effected. Read SEC document |
| May 08, 2024 Filed May 9, 2024 22:16 UTC | OSI SYSTEMS INC OSIS · Entity 4160 | SaleCommon Stock | 5,785 | $133.94 | $774,842.90 |
DisclosureSEC source: 0001415889-24-012758 · form4-05092024_100523.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,049 F1 · price: This transaction was executed in multiple trades at prices ranging from $133.18 to $134.16. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and price at which the transaction was effected. Read SEC document |
| December 14, 2023 Filed Dec 15, 2023 01:05 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionStock Options (right to buy) · Derivative | 4,277 | $0.00 Strike: $9.84 | $0.00 |
DisclosureSEC source: 0001415889-23-016502 · form4-12142023_081201.xml · derivative · entry 15 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,277 shares Expires 2024-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option, representing a right to purchase a total of 10,000 shares, was granted on 12-15-2014 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. F3 · derivative.expiration_date: This option, representing a right to purchase a total of 10,000 shares, was granted on 12-15-2014 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| December 14, 2023 Filed Dec 15, 2023 01:05 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 4,277 | $44.58 | $190,687.05 |
DisclosureSEC source: 0001415889-23-016502 · form4-12142023_081201.xml · nonDerivative · entry 10 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,348 F5 · price: This transaction was executed in multiple trades at prices ranging from $44.50 to $44.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 14, 2023 Filed Dec 15, 2023 01:05 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantCommon Stock | 4,277 | $9.84 | $42,085.68 |
DisclosureSEC source: 0001415889-23-016502 · form4-12142023_081201.xml · nonDerivative · entry 9 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,625 F3 · price: This option, representing a right to purchase a total of 10,000 shares, was granted on 12-15-2014 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 01:05 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionStock Options 9right to buy) · Derivative | 219 | $0.00 Strike: $9.84 | $0.00 |
DisclosureSEC source: 0001415889-23-016502 · form4-12142023_081201.xml · derivative · entry 14 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,277 Underlying: Common Stock · 219 shares Expires 2024-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option, representing a right to purchase a total of 10,000 shares, was granted on 12-15-2014 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. F3 · derivative.expiration_date: This option, representing a right to purchase a total of 10,000 shares, was granted on 12-15-2014 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 01:05 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionStock Options (right to buy) · Derivative | 5,000 | $0.00 Strike: $9.84 | $0.00 |
DisclosureSEC source: 0001415889-23-016502 · form4-12142023_081201.xml · derivative · entry 13 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,496 Underlying: Common Stock · 5,000 shares Expires 2024-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option, representing a right to purchase a total of 10,000 shares, was granted on 12-15-2014 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. F3 · derivative.expiration_date: This option, representing a right to purchase a total of 10,000 shares, was granted on 12-15-2014 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 01:05 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 219 | $43.61 | $9,551.40 |
DisclosureSEC source: 0001415889-23-016502 · form4-12142023_081201.xml · nonDerivative · entry 8 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,348 F4 · price: This transaction was executed in multiple trades at prices ranging from $42.25 to $43.67. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 01:05 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantCommon Stock | 219 | $9.84 | $2,154.96 |
DisclosureSEC source: 0001415889-23-016502 · form4-12142023_081201.xml · nonDerivative · entry 7 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,567 F3 · price: This option, representing a right to purchase a total of 10,000 shares, was granted on 12-15-2014 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 01:05 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 5,000 | $42.80 | $213,988.50 |
DisclosureSEC source: 0001415889-23-016502 · form4-12142023_081201.xml · nonDerivative · entry 6 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,348 F4 · price: This transaction was executed in multiple trades at prices ranging from $42.25 to $43.67. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 01:05 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantCommon Stock | 5,000 | $9.84 | $49,200.00 |
DisclosureSEC source: 0001415889-23-016502 · form4-12142023_081201.xml · nonDerivative · entry 5 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,348 F3 · price: This option, representing a right to purchase a total of 10,000 shares, was granted on 12-15-2014 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| December 12, 2023 Filed Dec 15, 2023 01:05 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionStock Options (Right to Buy) · Derivative | 504 | $0.00 Strike: $9.84 | $0.00 |
DisclosureSEC source: 0001415889-23-016502 · form4-12142023_081201.xml · derivative · entry 12 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,496 Underlying: Common Stock · 504 shares Expires 2024-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option, representing a right to purchase a total of 10,000 shares, was granted on 12-15-2014 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. F3 · derivative.expiration_date: This option, representing a right to purchase a total of 10,000 shares, was granted on 12-15-2014 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| December 12, 2023 Filed Dec 15, 2023 01:05 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionStock Options (Right to Buy) · Derivative | 468 | $0.00 Strike: $7.10 | $0.00 |
DisclosureSEC source: 0001415889-23-016502 · form4-12142023_081201.xml · derivative · entry 11 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 468 shares Expires 2024-09-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option, representing a right to purchase a total of 10,000 shares, was granted on 9-29-2014 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| December 12, 2023 Filed Dec 15, 2023 01:05 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 504 | $43.40 | $21,871.08 |
DisclosureSEC source: 0001415889-23-016502 · form4-12142023_081201.xml · nonDerivative · entry 4 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,348 F2 · price: This transaction was executed in multiple trades at prices ranging from $43.25 to $43.59. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 12, 2023 Filed Dec 15, 2023 01:05 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantCommon Stock | 504 | $9.84 | $4,959.36 |
DisclosureSEC source: 0001415889-23-016502 · form4-12142023_081201.xml · nonDerivative · entry 3 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,852 F3 · price: This option, representing a right to purchase a total of 10,000 shares, was granted on 12-15-2014 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| December 12, 2023 Filed Dec 15, 2023 01:05 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 468 | $43.40 | $20,308.86 |
DisclosureSEC source: 0001415889-23-016502 · form4-12142023_081201.xml · nonDerivative · entry 2 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,348 F2 · price: This transaction was executed in multiple trades at prices ranging from $43.25 to $43.59. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 12, 2023 Filed Dec 15, 2023 01:05 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantCommon Stock | 468 | $7.10 | $3,322.80 |
DisclosureSEC source: 0001415889-23-016502 · form4-12142023_081201.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,816 F1 · price: This option, representing a right to purchase a total of 10,000 shares, was granted on 9-29-2014 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| December 07, 2023 Filed Dec 11, 2023 23:00 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantRestricted Stock Units · Derivative | 2,393 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-016249 · form4-12112023_061202.xml · derivative · entry 5 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,144 Underlying: Common Stock · 2,393 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: On December 7, 2023, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2024. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F4 · derivative.expiration_date: On December 7, 2023, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2024. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 07, 2023 Filed Dec 11, 2023 23:00 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionRestricted Stock Units · Derivative | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-016249 · form4-12112023_061202.xml · derivative · entry 4 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,751 Underlying: Common Stock · 1,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On December 7, 2022, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F3 · derivative.expiration_date: On December 7, 2022, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 07, 2023 Filed Dec 11, 2023 23:00 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionRestricted Stock Units · Derivative | 1,036 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-016249 · form4-12112023_061202.xml · derivative · entry 3 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,036 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On December 7, 2021, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2022. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F2 · derivative.expiration_date: On December 7, 2021, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2022. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 07, 2023 Filed Dec 11, 2023 23:00 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionCommon Stock | 1,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-016249 · form4-12112023_061202.xml · nonDerivative · entry 2 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 07, 2023 Filed Dec 11, 2023 23:00 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionCommon Stock | 1,036 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-016249 · form4-12112023_061202.xml · nonDerivative · entry 1 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,598 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 04, 2023 Filed Dec 5, 2023 21:30 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionStock Options (Right to Buy) · Derivative | 4,273 | $0.00 Strike: $7.10 | $0.00 |
DisclosureSEC source: 0001415889-23-015865 · form4-12052023_041221.xml · derivative · entry 6 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 468 Underlying: Common Stock · 4,273 shares Expires 2024-09-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option, representing a right to purchase a total of 10,000 shares, was granted on 9-29-2014 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| December 04, 2023 Filed Dec 5, 2023 21:30 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 4,273 | $42.70 | $182,474.62 |
DisclosureSEC source: 0001415889-23-015865 · form4-12052023_041221.xml · nonDerivative · entry 4 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,562 F3 · price: This transaction was executed in multiple trades at prices ranging from $42.70 to $42.78. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 04, 2023 Filed Dec 5, 2023 21:30 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantCommon Stock | 4,273 | $7.10 | $30,338.30 |
DisclosureSEC source: 0001415889-23-015865 · form4-12052023_041221.xml · nonDerivative · entry 3 HAWKINS JAMES B · CIK 0000898243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,835 F1 · price: This option, representing a right to purchase a total of 10,000 shares, was granted on 9-29-2014 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.